Wednesday, February 10, 2010, 12:25am EST - Canadian Markets open in 9 hours and 5 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Urigen Pharmaceuticals, Inc. (URGP.OB)

On Feb 9: 0.15 USD   0.00 (0.00%)  
MORE ON URGP.OB
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
URIGEN PHARMACEUTCLS (OTC BB:URGP.OB) Delayed quote dataEdit
Last Trade: 0.15 USD
Trade Time: Feb 9
Change: 0.00 (0.00%)
Prev Close: 0.15
Open: 0.15
Bid: 0.14 x 5000
Ask: 0.15 x 5000
1y Target Est: 9.00
Day's Range: 0.14 - 0.15
52wk Range: 0.05 - 0.19
Volume: 13,000
Avg Vol (3m): 147,337
Market Cap: 11.06M
P/E (ttm): N/A
EPS (ttm): -0.03
Div & Yield: N/A (N/A%)
Urigen Pharmaceuticals, Inc. (URGP.OB)
1d  5d  3m  6m  1y  2y  5y  max 
 Add URGP.OB to Portfolio   Download Data

HEADLINES
URIGEN PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online (Fri, Jan 15)
Dan Vickery, PhD Joins Urigens Board
Business Wire (Thu, Jan 14)
Prof. Lowell Parsons Presents Urigen at One Med Place Conference in San Francisco on Jan. 13 at 4PM
Business Wire (Wed, Jan 13)
URIGEN PHARMACEUTICALS, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities, Financial Statements and Exh
EDGAR Online (Thu, Dec 31)
URIGEN PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure
EDGAR Online (Mon, Dec 21)
Urigen & Oceana Collaborate on FDA Meeting Preparation
Business Wire (Mon, Dec 21)
URIGEN PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online (Mon, Dec 7)
URIGEN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
EDGAR Online (Mon, Nov 16)
URIGEN PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure
EDGAR Online (Thu, Oct 29)
URIGEN PHARMACEUTICALS, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities
EDGAR Online (Wed, Oct 28)
More Headlines for URGP.OB...

ANALYST
EPS Est (next year) (Dec-69) : N/A
EPS Est (in 2 years) (Dec-69) : N/A
Avg Rec (current)*: 1.0
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Urigen Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapeutic products for urological disorders. Its products include URG101, which completed Phase II clinical trial for the treatment of painful bladder ...

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News Canadian Indices